Ariad Pharmaceuticals Inc fka ARIA

[Sikmarson]

COMBINATION CANCER THERAPY OF WEE1 AND MTOR INHIBITORS

The instant invention relates to methods for the treatment of cancer by administering a combination of a WEE1 inhibitor and an mTOR inhibitor. In one embodiment, the WEE1 inhibitor is WEE1-1 or a pharmaceutically acceptable salt thereof, or WEE1-2 or a pharmaceutically acceptable salt thereof, and the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus, a rapamycin-analog or a harmaceutically acceptable salt thereof.

Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US).
SHUMWAY, Stuart [US/US]; (US) (US only).
BENITA, Yair [IL/IL]; (IL) (US only).
FELDMAN, Igor [US/US]; (US) (US only).
O'NEIL, Jennifer [US/US]; (US) (US only).
BLOECHER, Andrew [US/US]; (US) (US only).
ARIAD PHARMACEUTICALS, INC. [US/US]; 26 Landsdowne Street Cambridge, Massachusetts 02139 (US)

?

patentscope